SUMMARY Thirty-two patients with polymyositis were categorised into 4 groups: (1) 'pure' polymyositis, (2) dermatomyositis, (3) myositis associated with autoimmune 'overlap syndrome', and (4) those with associated malignancy. Serum from each patient was examined for a range of antinuclear antibodies. Seventeen patients had ANA detected by immunofluorescence, 18 patients had raised DNA binding (>25 U/ml), of whom eight had levels greater than 50 U/ml (SI conversion: U/l= U/ml x 103.) Antibodies to soluble nuclear antigens were detected in 23 (72%) by 1 or more of 3 methods, and in all of these anti-RNP was the main antibody detected. Antibodies to other soluble antigens were also present in 6 sera. In 2 cases, both patients with SLE/myositis overlap, these were shown to be anti-Sm. The remaining 4 had antibodies to various protein components of the extracts, but it was not possible to demonstrate an antibody of diagnostic specificity for polymyositis. Furthermore, quantitation of anti-RNP and anti-DNA antibodies failed to define a distinct clinical entity or exclude malignant disease. High levels of anti-RNP antibodies showed an association with Raynaud's phenomenon, sclerodactyly, and pulmonary fibrosis and an inverse correlation with the rash of dermatomyositis, suggesting that this antibody may be of pathogenetic rather than diagnostic significance.
The aetiology of polymyositis is unknown, but immunological mechanisms are thought to play a part in its pathogenesis. Tissue Venables. that antibodies to the soluble nuclear antigen PM-1 are highly specific for polymyositis.7 The relationship of these antibodies to myositis associated with malignancy has not been established. The purpose of this study was to ascertain whether reactions to PM-1 occurred in our patients and if quantitation of antibodies to RNP, DNA, and Sm in patients with myositis identified distinct clinical syndromes such as MCTD or SLE and excluded those with associated malignant disease.
Patients and methods
The 32 patients selected for this study fulfilled at least 3 of the 4 criteria for myositis based on those previously described by Bohan et al. 8 The criteria were as follows: (1) symmetrical proximal muscle weakness; (2) raised creatine phosphokinase; (3) electromyographic changes characteristic of myositis (myopathic changes were not accepted); (4) high ENA antibody titres but was asymptomatic in 6 out of 7 patients. The exception (patient 21) died from pulmonary hypertension. Renal involvement was seen in 4 patients and restricted to the hightitre group. In only 1 patient, who had membraneous nephritis with nephrotic syndrome, was it clinically significant. In the remainder serum creatinine levels were normal, and proteinuria reversed after treatment with steroids.
In this study the titre of ENA antibodies correlated with the number of overlapping features. Thus, in all patients who in addition to their myositis had 2 or more of the above systemic features, ENA haemagglutination titres of 1:512 or greater were found.
DIAGNOSTIC SIGNIFICANCE OF ANTI-RNP AND OTHER ANTINUCLEAR ANTIBODIES
In our laboratory antibodies to R-NP were found in patients with SLE and RA (Table 2) , and are by no means specific for myositis. However, they did not appear to occur in patients with polymyalgia, muscular dystrophy, or neurogenic atrophy. In patients with polymyositis, antibodies to RNP were found in all 4 subgroups of the disease up to a titre of 1:4096. Titres higher than this were found only in the 'overlap' group. Antibodies to RNase resistant antigens were also restricted to the latter group, the 2 patients with anti-Sm both fulfilling ARA criteria for SLE. Antibodies to ds-DNA were above the upper limit of normal in all 4 groups of patients, and higher levels (>50 U/ml) occurred in 5 of the patients with overlap features, although in only 2 could a diagnosis of SLE be clinically supported. The presence of antinuclear antibodies in 4 out of 5 patients with an underlying malignant disease is particularly noteworthy. Of the 5 patients with carcinoma 3 had ANA demonstrated by immunofluorescence, 4 had raised DNA binding, and 3 had antibodies to RNP.
Discussion
In this study ANA ofvarying specificities, particularlyanti-ds-DNA and anti-RNP, occurred frequently in polymyositis. The association of polymyositis with ANA shown by immunofluorescence has been well established in the past with prevalences varying from 16 %8 to 37%.1 The much higher prevalence (60%) in our study probably reflects a bias in patient referral to a unit with a particular interest in connective tissue diseases. Previous authors have suggested that the presence of ANA in polymyositis reflects the presence of an associated 'collagen vascular disease'.14 Our data support this assumption to the extent that the highest levels were found in those patients who had a multi-system disease with overlap features of 2 or more autoimmune diseases, but we have shown that ANA can occur in polymyositis and dermatomyositis without underlying disease and in patients with an associated malignancy.
Recent reports have raised the possibility that antibodies to certain nuclear antigens may form the basis of a serological test of diagnostic specificity. Reichlin and Mattioli15 noted that sera from patients with polymyositis gave a specific reaction against a nuclear protein which could be demonstrated by an indirect complement fixation technique in 10 out of 17 (59 %). Wolfe et al.7 claimed to be able to demonstrate by double diffusion, a precipitin reaction with a nuclear protein antigen, termed PM-1, which was highly specific for polymyositis. In our study the sera of only 4 patients contained precipitins to protein antigens, although a number of thymus and lymphoid cell extracts were examined. These precipitins were clearly visible on CIE, but because only 2 yielded precipitins on double diffusion it was not possible to determine whether these reactions were directed to a specific protein such as PM-1. More recently by using a concentrated rabbit thymus extract we have shown that one of these precipitins (in a patient with myositis/scleroderma 'overlap syndrome') was anti-Scl-1. 16 This finding emphasises the heterogeneity of the precipitins that may be found in patients with myositis, and the need to characterise the antigen specificity of each reaction.
The very high prevalence (72 %) of anti-RNP antibodies in polymyositis sera in this study may be in part due to the fact that 24 patients were not receiving treatment at the time of the study and in part due to the large number of detection systems that were used. The use of 2 antigen preparations at different concentrations on double diffusion made this system very sensitive for the detection of anti-RNP. Thus the rabbit thymus extract gave precipitins with the 9 sera with relatively high anti-RNP haemagglutination titres. However, anti-RNP precipitins were detected in a further 10 sera (all with lower haemagglutination titres) using the calf thymus extract. This apparent discrepancy could be related to the source of the antigen, different methods of extraction, and higher concentration of RNP in the rabbit thymus extract. In spite of the sensitivity incurred by the use of a range of assay systems, anti-RNP antibodies could be demonstrated by all detection systems in 11 out of the 32 sera, giving a prevalence of 34% in this study. This is still a surprisingly high prevalence of anti-RNP antibodies for polymyositis and would initially seem to be in direct contrast to a number of previous reports.3 17 Antibodies to RNP are said to 
